CO4480033A1 - HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN RECEPTORS 1 - Google Patents

HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN RECEPTORS 1

Info

Publication number
CO4480033A1
CO4480033A1 CO96002329A CO96002329A CO4480033A1 CO 4480033 A1 CO4480033 A1 CO 4480033A1 CO 96002329 A CO96002329 A CO 96002329A CO 96002329 A CO96002329 A CO 96002329A CO 4480033 A1 CO4480033 A1 CO 4480033A1
Authority
CO
Colombia
Prior art keywords
accessory protein
receptor
antibody
interleukin receptors
human accessory
Prior art date
Application number
CO96002329A
Other languages
Spanish (es)
Inventor
Richard Anthony Chizzonite
Wong Ju Grace
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4480033A1 publication Critical patent/CO4480033A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

REIVINDICACIONES 1. UN POLINUCLEOTIDO QUE CODIFICA LA PROTEINA AC- CESORIA DEL RECEPTOR DE LA IL-1 o UN FRAGMENTO AC- TIVO DE LA MISMA. 14. LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 o UN FRAGMENTO ACTIVO DE LA MISMA. 21. UN ANTICUERPO QUE SE UNE ESPECIFICAMENTE A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1 HUMANA, Y QUE IMPIDE LA ACTIVACION DEL COMPLEJO DEL RECEP- TOR DE LA IL-1 MEDIANTE LA IL-1. 27. UN PROCEDIMIENTO PARA LA PREPARACION DE UN ANTICUERPO DE LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1, QUE COMPRENDE LOS PASOS SIGUIENTES: (a) PREPARACION DE UNA LINEA DE CELULAS DE HIBRI- DOMA QUE PRODUCEN UN ANTICUERPO MONOCLONAL QUE SE UNE ESPECIFICAMENTE A LA PROTEINA ACCESORIA DEL RECEPTOR DE LA IL-1, Y (b) PRODUCCION Y AISLAMIENTO DEL ANTICUERPO MONO- CLONAL. FIGURA 1CLAIMS 1. A POLYNUCLEOTIDE THAT CODES THE ACCESSORY PROTEIN OF THE IL-1 RECEPTOR or AN ACTIVE FRAGMENT OF THE SAME. 14. THE ACCESSORY PROTEIN OF THE IL-1 RECEPTOR or AN ACTIVE FRAGMENT OF THE SAME. 21. AN ANTIBODY THAT SPECIFICALLY Binds TO THE HUMAN IL-1 RECEPTOR ACCESSORY PROTEIN, AND THAT PREVENTS THE ACTIVATION OF THE IL-1 RECEPTOR COMPLEX BY IL-1. 27. A PROCEDURE FOR PREPARING AN IL-1 RECEPTOR ACCESSORY PROTEIN ANTIBODY, UNDERSTANDING THE FOLLOWING STEPS: (a) PREPARATION OF A LINE OF HYBRIDOMA CELLS THAT SPECIFICALLY BINDES TO THE ACCESSORY PROTEIN OF THE IL-1 RECEPTOR, AND (b) PRODUCTION AND ISOLATION OF THE MONO-CLONAL ANTIBODY. FIGURE 1

CO96002329A 1995-01-23 1996-01-22 HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN RECEPTORS 1 CO4480033A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
CO4480033A1 true CO4480033A1 (en) 1997-07-09

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96002329A CO4480033A1 (en) 1995-01-23 1996-01-22 HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN RECEPTORS 1

Country Status (19)

Country Link
EP (1) EP0808365A1 (en)
JP (1) JPH10512453A (en)
AR (1) AR003919A1 (en)
AU (1) AU4537096A (en)
BR (1) BR9606837A (en)
CA (1) CA2210724A1 (en)
CO (1) CO4480033A1 (en)
CZ (1) CZ208197A3 (en)
EA (1) EA199700265A1 (en)
FI (1) FI973089A (en)
HU (1) HUP9702458A2 (en)
IL (1) IL116796A0 (en)
MX (1) MX9705501A (en)
NO (1) NO973404D0 (en)
PE (1) PE64396A1 (en)
PL (1) PL321538A1 (en)
TR (1) TR199700652T1 (en)
WO (1) WO1996023067A1 (en)
ZA (1) ZA96333B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
JP2001526892A (en) 1997-12-23 2001-12-25 イミュネックス・コーポレーション SIGIRR DNA and polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7049095B2 (en) 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
YU103003A (en) 2001-06-26 2006-05-25 Abgenix Inc. Antibodies to opgl
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp Interleukin-1 receptors in the treatment of diseases
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
PT1729810T (en) 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Methods of reducing aggregation of il-1ra
PL1751175T3 (en) * 2004-05-05 2013-03-29 Valorisation Recherche Soc En Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
EP2366786A3 (en) * 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Cytokine receptor modulators and uses thereof
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
CA2824719C (en) 2011-01-19 2020-06-02 Cantargia Ab Anti-il1rap antibodies and their use for treating solid tumours
JP6153874B2 (en) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド Method for non-invasive prenatal ploidy calls
AU2012273153A1 (en) * 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP4428863A2 (en) 2015-05-11 2024-09-11 Natera, Inc. Methods and compositions for determining ploidy
EP3313887A2 (en) 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CN114835799A (en) * 2021-05-28 2022-08-02 百奥赛图江苏基因生物技术有限公司 Construction method and application of IL1RAP gene humanized non-human animal
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Also Published As

Publication number Publication date
AU4537096A (en) 1996-08-14
HUP9702458A2 (en) 1998-04-28
EA199700265A1 (en) 1998-04-30
TR199700652T1 (en) 1998-02-21
MX9705501A (en) 1997-10-31
PE64396A1 (en) 1997-01-28
NO973404L (en) 1997-07-23
WO1996023067A1 (en) 1996-08-01
CZ208197A3 (en) 1997-11-12
CA2210724A1 (en) 1996-08-01
EP0808365A1 (en) 1997-11-26
IL116796A0 (en) 1996-05-14
FI973089A0 (en) 1997-07-22
PL321538A1 (en) 1997-12-08
NO973404D0 (en) 1997-07-23
AR003919A1 (en) 1998-09-30
BR9606837A (en) 1998-05-26
FI973089A (en) 1997-07-22
ZA96333B (en) 1996-07-23
JPH10512453A (en) 1998-12-02

Similar Documents

Publication Publication Date Title
CO4480033A1 (en) HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN RECEPTORS 1
DK0578774T3 (en) Monoclonal antibodies against stem cell factor receptors
DE69429095D1 (en) HUMANIZED ANTIBODIES
CY1106594T1 (en) ANTIBODIES AGAINST HUMAN IL-12
BR0315123A (en) Erb-b1 receptor-directed pharmaceutical compositions
MY154009A (en) Anti-alpha v beta 6 antibodies
DK0668924T3 (en) Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
ATE178097T1 (en) MONOCLONAL ANTIBODIES TO THE ALPHA-PDGF RECEPTOR AND THEIR USES
ATE391174T1 (en) MODIFIED TPO AGONIST ANTIBODY
EA201300022A1 (en) THERAPEUTIC HUMAN MONOCLONAL ANTIBODY AGAINST IL-1R1
DK180380A (en) HYBRID CELL LINE AND PROCEDURES FOR PRODUCING AND USING THEREOF
ITFI930246A1 (en) BISPECIFIC MONOCLONAL ANTIBODY ANTI-CD3/ANTI-EGFR, PROCESS FOR PRODUCTION AND ITS USE.
ES2152216T3 (en) THERAPEUTIC USES OF THE HYPERVARIABLE REGION OF THE M195 MONOCLONAL ANTIBODY AND CONSTRUCTS OF THE SAME.
ES2038571T1 (en) PROCEDURE FOR THE PREPARATION OF SPECIFIC MONOCLONAL ANTIBODIES OF INTERLEUKINS 1ALFA AND 1BETA.
ATE279443T1 (en) A3C6E2, A MONOCLONAL ANTIBODY SPECIFIC TO THE HUMAN STEM CELL FACTOR (SCF) RECEPTOR
ES2110993T3 (en) MONOCLONAL ANTIBODIES SPECIFIC TO CLOSTRIDIUM DIFFICILE TOXIN B.
BR112021024544A2 (en) Anti-ceacam5 monoclonal antibody and method of preparation and use of same
MX2022005949A (en) Anti-ror-2 antibodies and methods of use.
DK407987D0 (en) APOLIPOPROTEIN B-SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMES PRODUCING THESE ANTIBODIES
KR900701318A (en) Anti-human high molecular weight-anti-idiotype antibody against melanoma related antigen
ES2061769T3 (en) MONOCLONAL ANTIBODY AND ITS USE.
ATE202117T1 (en) ANGIOTENSIN II RECEPTOR TYPE I SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMA
PT871612E (en) ISOINDOLONES COVERED AS PROTEIN INHIBITORS CINASE C
DK0569537T3 (en) Monoclonal antibodies against putative HCV envelope regions and methods for their use
ES2053637T3 (en) MONOCLONAL ANTIBODIES OF SUBSTANCE THAT LINKS ANTITHROMBINE AND ITS USES.